Michael Douglass

Berkshire Hathaway’s annual meeting is often referred to as “Woodstock for capitalists.” Join us to learn why… from someone who was there!

It sounds weird at first, but it makes sense.

More competition means lower prices -- and it's a good thing Gilead recognized that before its hand was forced.

A new survey shows just how low confidence is that workers are saving enough for retirement.

Some things never change -- and in healthcare, we sometimes feel like we’re talking about the same stuff year in and year out. Join us as we cover some stories that were a big deal in 2014, check in on how they’re going now, and predict some major trends in 2018.

The benefits are startling.

Berkshire Hathaway's annual meeting is Saturday. Here's why I'm going to Omaha.

Solid dividend, growth opportunities, aggressive management -- what's not to like?

Three positive indicators for the stock.

Two great dividend stocks, but only one can win.

It's down over 70% in the last year. Time to buy?

Biogen and Celgene are both great stocks. But there can be only one winner.

Two big dividend stocks -- but only one is a buy.

Do you really need a million dollars for retirement?

This is a key question for income investors, and the answer is less clear than the health insurer's history would suggest.

Anthem's management explains how the business is doing and what we can expect from here.

And do you have a backup plan ready?

With earnings rapidly incoming, here's what you need to watch for when Anthem reports on Jan. 27.

Gilead's latest deal is reminiscent of Celgene's M&A strategy.

Maybe. But more importantly, what will 2016 mean for 2017 and 2018?